anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sacral spinal cord injury (SSCI) can disrupt bladder neuromodulation and impair detrusor function. Current studies provide limited information on the histologic and genetic changes associated with SSCI-related neurogenic lower urinary tract dysfunction (NLUTD), resulting in few treatment options. This study aimed to establish a simple animal model of SSCI to better understand the disease progression. Ninety 8-week-old Sprague-Dawley (SD) rats were randomly separated into sham operation and SSCI groups. The SSCI group underwent sacral spinal cord injury, while the sham group did not. Urodynamic and histological assessments were conducted at various intervals (1, 2, 3, 4, and 6 weeks) post-injury to elucidate the disease process. Urodynamic examinations revealed significant bladder dysfunction in the SSCI group compared to the sham group, stabilizing around 3-4 weeks post-injury. Histological examination, including hematoxylin-eosin and Masson's trichrome staining, correlated these functional changes with bladder microstructural alterations. RNA-seq was performed on bladder tissues from the sham group and SSCI group at 6 weeks to identify differentially expressed genes and pathways. Selected genes were further analyzed using polymerase chain reaction (PCR). The findings indicated a pronounced inflammatory response in the first 2 weeks post-SSCI, progressing to bladder fibrosis at 3-4 weeks. In conclusion, this study presents a reliable, reproducible, and straightforward SSCI model, providing insights into bladder functional and morphological alterations post-SSCI and laying the groundwork for future therapeutic research.
AIM: To describe the trends of hospitalisation for infections in people with diabetes and in the general population.
METHODS: People with diabetes were identified from the Australian National Diabetes Services Scheme linked to hospitalisation datasets from 2010/11 to 2018/19. Data on hospitalisations in the general population were obtained from the Australian Institute of Health and Welfare. Joinpoint regression software was used to calculate the annual percentage change (APC) of rates.
RESULTS: The rate of hospitalisation for total infections increased with an APC of 2.6% (95% CI: 1.5, 3.7) among people with type 1 diabetes, 3.6% (2.6, 4.6) among people with type 2 diabetes, and 2.5% (1.3, 3.9) in the general population. Increasing rates were observed for sepsis, influenza, kidney infections, osteomyelitis, cellulitis, and foot infections in all groups. The rate of hospitalisation for urinary tract infection declined among people with type 2 diabetes though it was stable in other groups. The rate of hospitalisation for respiratory tract infections was stable among people with type 1 diabetes but increased in other groups. The rate of hospitalisation for gastrointestinal infection was stable in all cohorts.
CONCLUSION: Hospitalisation rates for infection have increased more rapidly over time in people with diabetes than in the general population.
BACKGROUND: This study evaluated the accuracy of an electronic monitoring system for assessing hand hygiene in a clinical setting in relation to direct observations.
METHODS: An electronic monitoring system was installed in a surgical ward at a tertiary hospital in Sweden. Hand hygiene events registered by the system were compared with direct observations conducted simultaneously by a trained observer following the World Health Organization's "My five moments for hand hygiene". A 4-step protocol was developed to evaluate the system's ability to accurately monitor hand hygiene in a clinical setting.
RESULTS: A total of 947 opportunities for hand hygiene were observed during June to December 2019. Of these, 484 opportunities were correctly captured by the electronic monitoring system and included in the calculations for accuracy. Sensitivity was 90.2% with a positive predictive value of 95.7%, while specificity was 50.0% with a negative predictive value of 29.0%. Overall accuracy was 87.1%.
CONCLUSIONS: Evaluating technical systems assessing hand hygiene in clinical settings is hampered by several challenges. The 4-step protocol helped to identify the limitations and strengths of the evaluated electronic monitoring system, revealing high accuracy while also detecting system errors.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of ALYQ™, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for ALYQ™ 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with ALYQ™ 40 mg was 4% compared to 5% in placebo-treated patients.

In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the ALYQ™ 40 mg group and occurring more frequently than with placebo.
<P>PROBLEM TO BE SOLVED: To provide an extracting method which is capable of obtaining the extract including a component of the 1-deoxynojirimycin derived from mulberry leaves at a high concentration from the mulberry leaves or the like.  <P>SOLUTION: The extracting method comprises step ST1 of natural seasoning of Moraceae of a variety selected from the group specified as Sen No. 307, Sen No. 322, Sen No. 335, Sen No. 416 and Sen K61, or of the excretions of silkworms, step ST2 of pulverizing a dried matter obtained, and thereafter step ST3 of extracting by the use of a solvent having principal components of water and alcohols. By making a ratio of the solvent to alcohols larger than 50 wt.%, a component of the 1-deoxynojirimycin derived from mulberry leaves becomes a higher concentration in the solvent.  <P>COPYRIGHT: (C)2011,JPO&INPIT
There is a growing demand for implant dentistry as the first rehabilitation choice for treating patients with missing teeth. Clinicians can encounter asymptomatic retained root fragments in edentulous spaces. This case report presents the long-term prognosis of an implant resulting in late failure with an osteointegrated root remnant on the fixture 11 years after implant placement. A 68-year-old female patient presented to the clinic with complaints of function related to a maxillary right 4-unit implant-supported bridge 11 years after the first insertion of the implants. After removal of the restoration, a root remnant was observed as osteointegrated on the fixture of the middle supporting implant. The implant was placed encroaching upon the mesial part of the residual root fragment left unintentionally, which was discovered accidentally during bridge removal. Clinicians should show ultimate attention when utilizing the retained root remnants in implant sites considering the potential risk of hindering osteointegration. However, osteointegration of the encroached implant and root fragment is plausible, with no observed adverse effects. A risk-benefit evaluation should be assessed individually.
In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
The aim of this study was to investigate whether adolescent with idiopathic scoliosis receiving scoliosis specific exercise approach, such as SEAS exercises, in accordance with the bracing approach for moderate curves would have greater improvement in curve progression, trunk deformity, body symmetry and quality of life than adolescent receiving exercise therapy based on the general core stabilization approach with similar intensity. Thirty female patients with AIS aged 12 to16 years, who have moderate curves (20 to 45 degree) randomly divided into two groups. One group received CS exercise, while other received SEAS exercise for forty-min once weekly for four months. Both groups underwent full-time bracing (23 hours per day) intervention. Outcome was based on Cobb angle, angle of trunk rotation, body symmetry (Posterior Trunk Symmetry Index), cosmetic trunk deformity (Walter Reed Visual Assessment Scale) and quality of life (Scoliosis Research Society - 22 Questionnaire) measured at baseline and after intervention period. Results were analyzed using the paired sample t-test to compare repeated measurements and independent sample t-test to compare the groups.
The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
Solitary bone plasmacytoma (SBP) is a localised proliferation of malignant plasma cells (PCs) in the skeleton. The annual UK incidence is 0.4/100,000 (lower than multiple myeloma (MM)) with a peak age incidence at 68 years and there are estimated to be about 260 new cases per year in the United Kingdom (UK). The majority of patients with SBP ultimately progress to myeloma and this is likely due to occult disease not detected by conventional staging methods. Standard care for these patients is involved field radiotherapy (IFRT), but despite radical doses, two-thirds develop multiple myeloma at a median of 2 years, more so if there are high risk features.

The IDRIS Trial is a phase III study where the investigators hope to demonstrate that adjuvant lenalidomide + dexamethasone following IFRT prevents the development of multiple myeloma in patients with high risk solitary bone plasmacytoma. Whilst a proportion of solitary bone plasmacytoma is cured with IFRT, it is clear that the majority will progress to multiple myeloma. The investigators are seeking to prevent this outcome by using adjuvant therapy in this study.
The utility model discloses a dental implant, which comprises a body 1, an expansion core 3 in the body 1, and a repair drill base 2 connected above the body, wherein the body 1 is respectively embedded with the expansion core 3 and the repair drill base 2 by threads. The outer surface of the body 1 is covered with a multi-hole tantalum layer 4. The outer surface of the bottom end of the body 1 is a semi-spherical surface. The body 1 is in a hollow structure, the upper section of the inner wall of the body is provided with internal threads 5, and the internal threads 5 can enable the expansion core 3 to rotate along the threads and move up and down. The lower section of the inner wall of the body 1 is divided equally along a long axis and is provided with three seams running through the inner wall and an outer wall. The lower end of the hollow inner wall of the body 1 is provided with an inverted cone-shaped necking body, and the inner wall is smooth. A neck shoulder 7 of the body 1 is an external diameter extending body of the body 1, the inner side of the neck shoulder 7 is in an inverted cone-shaped structure, and the outer surface of the neck shoulder 7 is a smooth surface. The dental implant with the structure can adapt to various sclerotins, stable retention is effectively realized, the initial stability is high, the connecting tightness with the human body tissue is high, and the biological compatibility is good.
Providers may use mobile devices to access mobile drug sampling services from a drug sample promotional ecosystem. The drug sample promotional ecosystem includes a promotional orchestration engine which comprises a services engine that provides transactional responses to a provider's request, such as informational results being returned to the provider or request for further actions that will be forwarded. An analysis engine stores data and provides tactical and strategic level analysis. The learning engine is a mechanism by which the promotional orchestration engine adapts itself to changing conditions. The learning engine preferably customizes various components of the services engine and components of the analysis engine. From a provider's standpoint, the learning engine allows components of the services engine to be personalized to the particular provider.
The invention relates to a traditional Chinese medicine for treating leukemia. The traditional Chinese medicine comprises the components as follows: 150-170 g of buffalo horns, 150-170 g of indigo naturalis, 150-170 g of moutan bark, 110-130 g of scutellaria baicalensis, 150-170 g of oldenlandia diffusa, 150-170 g of astragalus membranaceus, 58-62 g of coptis chinensis, 78-82 g of rehmannia and 18-22 g of American ginseng. A formula of the traditional Chinese medicine also can comprise the components as follows: 10-15 g of honeysuckles, 15-30 g of houttuynia cordata, 6-12 g of cacumen biotae and 3-15 g of folium artemisiae argyi. All the components are combined, functions of benefiting qi and nourishing blood, detoxifying and clearing marrow, cooling and activating blood and enabling juvenile cells to be subjected to differentiation and apoptosis are realized. The traditional Chinese medicine is used for treating poison stasis incubation, a qi-blood deficiency syndrome and various types of acute and chronic leukemia. By means of clinical application for many years, the effect is clear, and the toxic and side effects are small.
Patients receive ONC201 PO QW or Q3W for 12 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study.
The invention discloses a medicament for treating vascular dementia, in particular a combined medicament for treating the vascular dementia. The combined medicament contains higenamine and icariin which are preparations with same specification and unit or different specifications and units and are used for simultaneously mediating or respectively mediating as well as a pharmaceutically acceptable carrier. The invention also discloses a pharmaceutical composition for treating the vascular dementia. The pharmaceutical composition is a preparation prepared from the following raw materials by weight proportion: the weight ratio of the higenamine to the icariin is 1 to (1 to 10). The invention further discloses a preparation method and application of the composition. According to the medicament disclosed by the invention, the higenamine and the icariin are combined for use, so that the vascular dementia can be effectively treated; the medicament is broad in application prospect.
5-Fluorouracil (5-FU) is an anticancer agent belonging to BCS Class III that exhibits poor release characteristics and low retention in the biological system. The main objective of this investigation was to develop a drug delivery system, i.e., Nanostructure Lipid Carriers (NLCs) loaded with 5-FU to prolong its biological retention through 5-FU-loaded NLCs (5-FUNLC) were designed to manipulate physicochemical characteristics and assessment of in vitro and in vivo performance. The developed NLCs underwent comprehensive characterization, including assessments for particle size, zeta potential, morphological evaluation, and FT-IR spectroscopy. Additionally, specific evaluations were conducted for 5-FUNLCs, encompassing analyses for encapsulation efficiency of the drug, release characteristics in PBS at pH 6.8, and stability study. The lipophilic character of 5-FUNLC was confirmed through the measurement of the partition coefficient (log P). 5-FUNLCs were observed as spherical-shaped particles with a mean size of 300 ± 25 nm. The encapsulation efficiency was determined to be 89%, indicating effective drug loading within the NLCs. Furthermore, these NLCs exhibited a sustained release nature lasting up to 3-4 h, indicating their potential for controlled drug release over time. Lipid components were biocompatible with the 5-FU to determine thermal transition temperature and show good stability for 30 days. Additionally, an in vitro hemolysis study that confirmed the system did not cause any destruction to the RBCs during intravenous administration. The drug's gut permeability was assessed utilizing the optimized 5-FUNLC (F2) in comparison to 5-FU through the intestine or gut sac model (in the apical to basolateral direction, A → B). The permeability coefficient was measured as 4.91 × 10-5 cm/h with a significant difference. Additionally, the antioxidant potential of the NLCs was demonstrated through the DPPH method. The NLCs' performance was further assessed through in vivo pharmacokinetic studies on Wistar Rats, resulting in a 1.5-fold enhancement in their activity compared to free 5-FU. These NLCs offer improved drug solubility and sustained release, which collectively contribute to enhanced therapeutic outcomes and modulate bioavailability. The study concludes by highlighting the potential of 5-FUNLC as an innovative and efficient drug delivery system. The findings suggest that further preclinical investigations are warranted, indicating a promising avenue for the development of more effective and well-tolerated treatments for cancer.
A stable, food-compatible liposome is prepared by dissolving a lipophilic material in a phospholipid followed by the addition of water or an aqueous solution and mixing by sonicating to producing a liposome having the lipophilic material encapsulated in the lipid bilayer. The preferred lipophilic materials include any readily oxidizable lipid and in particular the omega-3 fatty acid containing fish oils. Other lipophilic materials which can be encapsulated in the lipidic bilayer include flavorants, acidulants, preservatives and antioxidants. The resulting liposomes provide a stabilizing vehicle for the lipophilic materials to reduce the occurrence of oxidation and rancidity. Liposomes prepared according to the disclosed method exhibit none of the unpleasant odor and flavor characteristics normally associated with oxidized or rancid oils. The liposomes provide an extended shelf life of the unstable oils and can be added directly to the food product as a dispersion during the manufacturing stage or dried to a free flowing powder for later use.
During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
The cream for skin care contains structure-forming components, the oil phase, the moistening agents, the preserving agents, the active additives, the water, lanolin, and Trilon B. The emulsion wax andstearin are used as the structure-forming components. The oil phase comprises the sunflower oil and the coconut oil. Polyminerals comprising magnesium, zinc, iodine, potassium, calcium, copper, selenium, iron, gold, and silver constitute the active additives. Silcom, the bees wax, stearate PEG-400, oleate PEG-400, and the hydrated castor oil PEG-40 are used as the additional structure-forming components. The cacao oil, the oil from the grape, and the oil from the pumpkin seeds are used as the additional components of the oil phase. Alantoin and urea are used as the moistening agents.
Upon providing informed consent, subjects will be sequentially enrolled into the study. Decision regarding dose escalation will be based on the recommendation from the Data Monitoring Committee (DMC). The first 3 eligible subjects will receive the low dose of AXT107 injection. After the 3 low dose subjects complete a 7-day follow-up, the DMC will review their safety data. If an acceptable safety profile is determined by the DMC, 3 additional subjects will be enrolled to receive the mid dose of AXT107 injection. Upon completion of a 7-day follow-up, review of the safety data, and determination of an acceptable safety profile by the DMC for the mid dose subjects, 3 additional subjects will be enrolled to receive the high dose of AXT107 injection.
Every year, 80,000-100,000 ablation procedures take place in the United States and approximately 1% of these involve paediatric patients. As the paediatric population undergoing catheter ablation to treat dysrhythmia is constantly growing, involvement of anaesthesiologists in the cardiac electrophysiology laboratory is simultaneously increasing. Compared with the adult population, paediatric patients need deeper sedation or general anaesthesia (GA) to guarantee motionlessness and preserve comfort. As a result, the anaesthesiologist working in this setting should keep in mind heart physiopathology as well as possible interactions between anaesthetic drugs and arrhythmia. In fact, drug-induced suppression of accessory pathways (APs) conduction capacity is a major concern for completing a successful electrophysiology study (EPS). Nevertheless, the literature on this topic is scarce and the optimal type of anaesthesia in EPS and ablation procedures in children is still controversial. Thus, the main goal of the present review is to collect the literature published so far on the effects on cardiac conduction tissue of the drugs commonly employed for sedation/GA in the cath lab for EPS and ablation procedures to treat supraventricular tachycardia in patients aged <18 years.